Delisting riskPopularity #4,664
Cardio Diagnostics (CDIO)
Develops genetic-epigenetic blood tests and clinical intelligence for coronary heart disease.
$1.89
vs last close−0.03 (−1.56%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 6.52% | 193.0K shares | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Insiders | 2.09% | 61.8K shares | |
| 2 holders · as of Oct 9, 2024 | |||
| Other | 91.39% | 2.70M shares | |
| remainder | |||
2.96M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
17 holders · 193.0K shares · 4 new positions · 5 increased · 5 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Renaissance Technologies LLC | 49.2K | 1.66% | +33.9K | Aug 13, 2026 |
| BlackRock, Inc. | 34.7K | 1.17% | 0 | Aug 7, 2026 |
| Geode Capital Management, LLC | 26.2K | 0.89% | −5.9K | Aug 12, 2026 |
| Vanguard Capital Management LLC | 20.2K | 0.68% | 0 | Aug 13, 2026 |
| Citadel Advisors LLC | 19.1K | 0.64% | +19.1K | Sep 2, 2026 |
| XTX Topco Ltd | 16.1K | 0.54% | +16.1Knew | Aug 14, 2026 |
| Jane Street Group, LLC | 11.9K | 0.40% | −69.4K | Aug 14, 2026 |
| State Street Corp | 10.1K | 0.34% | +10.1Knew | Aug 7, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.
